rituximab-pvvr Ruxience
Selected indexed studies
- Rituximab. (, 2006) [PMID:30000857]
- Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022. (Am J Manag Care, 2024) [PMID:39745502]
- Rituximab reference vs biosimilar utilization for oncology vs nononcology indications. (Am J Manag Care, 2023) [PMID:37948656]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database. (2025) pubmed
- Rituximab. (2006) pubmed
- Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022. (2024) pubmed
- Rituximab reference vs biosimilar utilization for oncology vs nononcology indications. (2023) pubmed
- Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. (2021) pubmed
- Rituximab-pvvr is not an independent predictor for infusion reactions in a cohort given rituximab-pvvr or rituximab: A single-center retrospective study. (2022) pubmed
- Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA. (2021) pubmed
- Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare. (2026) pubmed